Treatment of cancer with dihydropyrazino-pyrazines
US9630966B2 · kind B2 · utility
4Cited by
21References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 16, 2014 |
| Grant date | Apr 25, 2017 |
| Priority date | — |
| Expiry date | Apr 16, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q1/6886
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.